Dresden, Germany
Dresden, Germany

Time filter

Source Type

News Article | February 24, 2017
Site: www.eurekalert.org

Mild cognitive impairment (MCI), a condition that often predates Alzheimer's disease (AD), can be remotely detected through a self-administered virtual reality brain training game. Thessaloniki, Greece, February 23, 2017 - Greek researchers demonstrated the potential of a self-administered virtual supermarket cognitive training game for remotely detecting mild cognitive impairment (MCI), without the need for an examiner, among a sample of older adults. MCI patients suffer from cognitive problems and often encounter difficulties in performing complex activities such as financial planning. They are at a high risk for progressing to dementia however early detection of MCI and suitable interventions can stabilize the patients' condition and prevent further decline. It has been shown that virtual reality game-based applications and especially virtual supermarkets can detect MCI. Past studies have utilized user performance in such applications along with data from standardized neuropsychological tests in order to detect MCI. The team that conducted this study was the first scientific team to achieve reliable MCI detection using a virtual reality game-based application on its own. In that previous study , administration of the virtual super market (VSM) exercise was conducted by an examiner. The present study eliminated the need for an examiner by calculating the average performance of older adults using a special version of the VSM application, the VSM Remote Assessment Routine (VSM-RAR), at home on their own, for a period of one month. It is the first instance where a self-administered virtual reality application was used to detect MCI with a high degree of reliability. The research team included scientists from the Aristotle University of Thessaloniki (AUTH), the Centre for Research and Technology Hellas/Information Technologies Institute (CERTH/ITI), the Greek Association of Alzheimer's Disease and Related Disorders (GAADRD) and the Network Aging Research (NAR) of the University of Heidelberg. In an article published in the Journal of Alzheimer's Disease, the researchers have indicated that the virtual supermarket remote assessment routine (VSM-RAR) application displayed a correct classification rate (CCR) of 91.8% improving VSM's CCR as assessed in the previous VSM study while achieving a level of diagnostic accuracy similar to the most accurate standardized neuropsychological tests, which are considered the gold standard for MCI detection. Self-administered computerized cognitive training exercises/games are gaining popularity among older adults as an easy and enjoyable means of maintaining cognitive health. Such applications are especially popular among older adults who consider themselves healthy and are not inclined to visit specialized memory clinics for cognitive assessment. If self-administered games and exercises could also detect cognitive disorders, initial cognitive screening could be conducted remotely. The wide implementation of this method of remote screening would facilitate the detection of cognitive impairment at the MCI stage thus allowing for more efficient therapeutic interventions. This preliminary study indicates that automated, remote MCI screening is feasible. This method could be utilized to screen the majority of the older adult population, as it dramatically lowers examination-related costs. The social and economic benefits, especially caregiver and healthcare service burden, of the early detection of cognitive disorders could be enormous. At the same time, as older adults are becoming increasingly computer savvy, it is important to create software that meets their needs and allows them to remain healthy and active. Out team continues its research on the VSM with the aim of improving its usability, shortening its administration time and supplementing the science behind VSM with additional data. The Journal of Alzheimer's Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. The Journal of Alzheimer's Disease has an Impact Factor of 3.612 according to Thomson Reuters' 2013 Journal Citation Reports. It is ranked #22 on the Index Copernicus Top 100 Journal List. The Journal is published by IOS Press.


Leading product development, IT, and manufacturing teams to exchange best practices for IoT, Digital Thread, and digital transformation in Nashville. Andover, MA, February 25, 2017 --( For details, agenda, and registration visit: www.aras.com/ACE2017 Driving the Business of Engineering for Complex Product Development Each year, ACE brings together global industry and technology leaders to exchange best practices on managing complex product development and transforming the science of engineering to the business of engineering. ACE 2017 features business presentations from Huntington Ingalls, Microsoft, Valley Fine Foods, IBM, Akrapovič, Carestream, Sandia, Lord, Pabst, and other industry leaders. In addition, application and demo tracks feature overviews of the latest version of the Aras PLM Platform, including MPP, Tech Docs, and Quality Management, and presentations on PLM implementation strategy. Conference sponsors include IBM, Accenture, Infor, Aessis, Institute of Configuration Management, ITI, Kisters, Minerva, No Magic, Prolim, PSC Group, Razorleaf, SofTech Group, The vdR Group, XPLM Solution, Zionex, and Zuken. About Aras We offer the best Product Lifecycle Management (PLM) software for global businesses with complex products and processes. Resilient PLM platform technology makes Aras more scalable, flexible and upgradable for the world’s largest organizations, and a full set of applications provide complete functionality for the business of engineering. Customers include Airbus, GE, Hitachi, Honda, Kawasaki, Motorola and XEROX. Aras is privately held with global headquarters in Andover, Mass. More at www.aras.com and Twitter @aras_plm Andover, MA, February 25, 2017 --( PR.com )-- Aras®, the next leader in enterprise Product Lifecycle Management (PLM) software, today announced key industry presentations and sessions for ACE 2017, the company’s marquee customer conference taking place on March 21st to 23rd in Nashville, TN. The gathering is the premier event that connects the most innovative product development, IT, and manufacturing teams from Automotive, Aerospace & Defense, High Tech Electronics, and Industrial Manufacturing to shape the future of PLM.For details, agenda, and registration visit: www.aras.com/ACE2017Driving the Business of Engineering for Complex Product DevelopmentEach year, ACE brings together global industry and technology leaders to exchange best practices on managing complex product development and transforming the science of engineering to the business of engineering.ACE 2017 features business presentations from Huntington Ingalls, Microsoft, Valley Fine Foods, IBM, Akrapovič, Carestream, Sandia, Lord, Pabst, and other industry leaders. In addition, application and demo tracks feature overviews of the latest version of the Aras PLM Platform, including MPP, Tech Docs, and Quality Management, and presentations on PLM implementation strategy.Conference sponsors include IBM, Accenture, Infor, Aessis, Institute of Configuration Management, ITI, Kisters, Minerva, No Magic, Prolim, PSC Group, Razorleaf, SofTech Group, The vdR Group, XPLM Solution, Zionex, and Zuken.About ArasWe offer the best Product Lifecycle Management (PLM) software for global businesses with complex products and processes. Resilient PLM platform technology makes Aras more scalable, flexible and upgradable for the world’s largest organizations, and a full set of applications provide complete functionality for the business of engineering. Customers include Airbus, GE, Hitachi, Honda, Kawasaki, Motorola and XEROX. Aras is privately held with global headquarters in Andover, Mass. More at www.aras.com and Twitter @aras_plm Click here to view the list of recent Press Releases from Aras Corporation


ESI Group (Paris:ESI) (FR0004110310 – ESI), pioneer and leader in Virtual Prototyping solutions, today announces the acquisition of Scilab Enterprises SAS, publisher of Scilab, widely regarded as the most compelling open source alternative to MATLAB®1, the commercial software for analytical numerical solutions. Scilab provides a world class powerful environment for engineering computation and scientific applications. Commenting on this acquisition, Vincent Chaillou, ESI Group’s COO, said: “This acquisition fits perfectly with ESI Group’s technology investment strategy. It is aligned with our objective to expand our user base to include all stakeholders involved in the industrial product creation process, starting from the earliest stages of analytical modeling. It paves the way towards the more elaborate 3D-4D numerical simulations of the full Virtual Prototyping and eventually of the all-encompassing “Immersive Virtual Engineering” transformative solutions of Industry 4.0.” Raphaël Auphan, CEO of Scilab Enterprises, said: “We are very enthusiastic about joining ESI, a numerical simulation and Virtual Prototyping global leader, to bring Scilab to a wider range of industrial, academic and research players. Our shared vision will provide the engineering community with the latest generation of analytical solutions to meet current and future numerical simulation challenges." A global community with more than a million engineering users Scilab Enterprises was created in 2010 out of the Scilab Consortium, which was itself created in 2003 as part of an initiative backed by INRIA, the French National Institute for computer sciences and applied mathematics. Scilab (SCIentific LABoratory) is an open-source multiplatform analytical numerical computation software and scientific & engineering programming language. First introduced in 1980 it is now engaging an active community of over a million engineering users and development partners in diverse industries and in education. With its wide range of mathematical functions, graphic interfaces, graphs and algorithms, Scilab enables users to build their own applications for numerical analysis, system modeling, data analytics, optimization, signal and image processing, embedded and control systems, up to test and measurement interfaces. Beyond publishing Scilab and offering Scilab consulting services, Scilab Enterprises offers as well “Scilab Cloud” for the web deployment in Software as a Service (SaaS) mode of scientific and engineering applications. This enables organizations and individuals to publish and manage the web-based use of their own Scilab applications. Thanks to its ability to interconnect with third-party codes, technologies and applications, Scilab can also serve as a single scientific and technical computing platform. Building on that capability Scilab Enterprises now offers a scientific and technological “Platform as a Service” (PaaS) to enable countless numbers of public and private enterprises as well as individual engineers and scientists to monetize applications written in different programming languages by facilitating their distribution, back-up and use. Importantly, applications exploiting Scilab’s many computational functions can be accessed by an unlimited number of users as the software is open source. A powerful vector for the democratization of ESI Group’s Virtual Prototyping and Immersive Virtual Engineering solutions The acquisition of Scilab will help expand ESI Group’s footprint in the product pre-design stage and early analytical phase. Starting with the recent acquisition of ITI, and its SimulationX (0D-1D) system modeling software, this expansion is part of the Group’s transformative and disruptive change strategy focused on front-loading the power of computer modeling to everyone involved in the product development process. Already engineers working in the frame of conventional “Product Lifecycle Management” (PLM) benefit from use of mathematical analytical models, built around Scilab, to quickly explore design options with simple (0D) models, before embarking into detailed (0D-1D to 3D-4D) modeling based design, certification and production. In ESI’s PLM disruptive vision, the next step to Virtual Prototyping is to follow the life of the product after its development and certification phases, to cover its actual, real life in operation. Now within the new methodological approach of the “Product Performance Lifecycle” (PPL) innovative modeling, the ‘as built’ Virtual Prototype is transformed into its “Hybrid Virtual Twin”, with ‘data driven’ updates from sensors in actual operations. Here mathematical models of the product - along with its real or virtual life sensors and control systems - are key to provide reliable predictive prototyping. In this fully “End to End” vision of innovative product development and subsequent piloting in real life operational conditions, the acquisition of Scilab Enterprises equips ESI to address the full spectrum of early engineering needs, from simple, but physically realistic models, all the way to the “as manufactured” and “as operated” virtual products that customers build today and develop for tomorrow assisted or autonomous products. Following ESI’s recent successful acquisition and integration of OpenCFD, specializing in developments and services for OpenFOAM®, an open source software for broad band numerical simulation in the field of Fluid Mechanics, this current operation substantiates the Group’s commitment to the open source business model to foster the disruptive moves that will democratize Virtual Engineering solutions “for all”. It will provide beneficiaries with greater freedom to customize applications and to tailor them to their own flexible and affordable needs. In this regard, Scilab’s incorporation into ESI’s global eco-system is expected to be a major catalyst in easing and speeding up the digital transformation of innovative industrial product development. Scilab Enterprises is naturally synergetic with ESI Group, both in technology and business opportunities. The existing ESI Cloud offering will be greatly boosted by this acquisition and by Scilab’s reputation with a very large global community of users in diverse industries and academic circles. It also represents a major asset that will help to increase ESI’s global visibility and eventually to unlock valuable commercial opportunities. Moreover, the dynamic presence of Scilab in the educational community worldwide will immediately expand ESI’s footprint in that all important sphere. Financial aspects of the operation The operation is being financed mainly by the transfer of some ESI Group treasury shares to the shareholders of Scilab Enterprises. Scilab’s development platform and team will be rapidly integrated into ESI’s operating structure. You can find all of our press releases at: www.esi-group.com/company/press As publisher of Scilab modeling and simulation software, Scilab Enterprises has a small expert team with a unique mix of applied mathematicians and computer science engineers. Scilab is an open source software used widely in the scientific & engineering community (100 000 downloads every month worldwide). Scilab is used for modeling & simulation and scientific post-processing in industrial companies as well as in education & research. Scilab Enterprises offers on the one hand professional services in numerical computing and on the other hand provides the Scilab Cloud platform for the cloud deployment of scientific and engineering applications. For more information, please visit http://scilab.io/ ESI Group is a leading innovator in Virtual Prototyping software and services. Specialist in material physics, ESI has developed a unique proficiency in helping industrial manufacturers replace physical prototypes by virtually replicating the fabrication, assembly and testing of products in different environments. Coupled with Virtual Reality, animated by systems modeling, and benefiting from data analytics, Virtual Prototyping has become immersive, shared and interactive. ESI’s customers can bring their products to life, ensuring reliable ‘as built’ performance, serviceability and maintainability. ESI solutions help world-leading OEMs and innovative companies anticipate and make sure that their products will pass certification tests - before any physical prototype is built - and that their new products are competitive when entering their market space. Recently, ESI has undertaken a major transformative adaptation of its Virtual Prototyping solutions into “Hybrid Virtual Twins”, to enter the new paradigm of “Product Performance Lifecycle” (PPL), which addresses, beyond the development phase, the life of the new product in its full operational cycle from launch to retirement. Riding the new age of ubiquitous sensors connected to the Internet of Things (IoT), PPL answers the emerging needs of industrial manufacturers to relentlessly create innovative products that are smart, assisted and autonomous. ESI’s customer base spans major industry sectors. The company employs more than 1200 high-level engineers, scientists and domain specialists worldwide, to address the needs of customers in more than 40 countries. ESI Group is listed in compartment B of NYSE Euronext Paris and is granted “Entreprise Innovante” (Innovative Company) certification since 2000 by Bpifrance. ESI is eligible for inclusion in FCPI (venture capital trusts dedicated to innovation) and PEA PME. For more information, please visit www.esi-group.com/


Vincent Chaillou, Directeur Général Délégué d’ESI Group, déclare : « Cette acquisition s’inscrit parfaitement dans la poursuite des investissements technologiques déjà réalisés par ESI Group. Elle est en ligne avec notre objectif qui vise à étendre notre base d’utilisateurs scientifiques à tous les acteurs impliqués dans la conception et la création de produits industriels dès la première étape de la modélisation analytique. Cette extension ouvre la voie vers les simulations numériques 3D-4D plus élaborées du Prototypage Virtuel et ultérieurement vers les solutions globales et transformatrices de «l’Ingénierie Virtuelle Immersive» de l’Industry 4.0 et de l’Outcome Economy. » Raphaël Auphan, Directeur Général de Scilab Enterprises déclare : « Nous sommes enthousiastes à l’idée de rejoindre ESI, un leader mondial de la simulation numérique et du Prototypage Virtuel, pour porter Scilab auprès d’un ensemble plus large d’acteurs industriels, académiques et de la recherche. Notre vision commune permettra d’apporter à la communauté des ingénieurs et autres scientifiques, des solutions analytiques de dernière génération pour répondre aux enjeux actuels et futurs de la simulation numérique. » Scilab est un produit open source de calcul numérique analytique multiplateformes et un langage de programmation scientifique au mieux de l’état de l’art. Introduit en 1980, Scilab rassemble aujourd’hui une communauté active de plus d'un million d'utilisateurs en ingénierie, ainsi que de nombreux partenaires de développement dans divers secteurs industriels ou éducatifs. Avec sa large gamme de fonctions mathématiques, d’interfaces graphiques, de graphes et d'algorithmes, Scilab permet aux utilisateurs de construire leurs propres applications pour l’analyse numérique, la modélisation des systèmes, l'analyse des données, l’optimisation, le traitement du signal et de l'image, les systèmes de contrôle embarqués et les tests et mesures. En plus d’être l’éditeur de Scilab, et le réalisateur de Services de conseil et d’expertise, Scilab Enterprises propose également la plateforme ‘Scilab Cloud’ pour le déploiement d'applications scientifiques et d’ingénierie en mode ‘Software as a Service’ (SaaS) permettant aux entreprises et aux scientifiques de publier et de gérer le déploiement web de leurs propres applications basées sur Scilab. Grâce à ses capacités d'interconnexion avec des progiciels, des technologies et des applications tierces, Scilab peut aussi jouer le rôle de plateforme unique. En effet Scilab Enterprises propose désormais une plateforme scientifique et technologique en tant que Service (‘Platform as a Service’ - PaaS) pour permettre à un nombre considérable d'entreprises publiques et privées et d’ingénieurs ou scientifiques de commercialiser des applications écrites dans différents langages de programmation en facilitant leur distribution, leur sauvegarde, leur utilisation et donc leur monétisation. Enfin, le logiciel étant basé sur un code source ouvert, les nombreuses fonctions de calcul de Scilab sont accessibles par un nombre illimité d'utilisateurs. L’acquisition de Scilab Entreprises contribuera à l’élargissement du positionnement d’ESI Group aux phases amont de la conception et de l’analyse des produits industriels. Initié dans ESI suite à l’acquisition d’ITI, et de son logiciel de modélisation des systèmes SimulationX (modèles de dimensions ‘0D-1D’), l’élargissement de ce positionnement s’inscrit dans la stratégie de transformation de rupture menée par le Groupe visant à apporter très tôt la puissance de la modélisation informatique à tous les intervenants du processus de développement des produits industriels. Les ingénieurs travaillant dans le cadre d’une approche traditionnelle de type PLM (Product Lifecylce Management) utilisent déjà des modèles mathématiques analytiques, construits à l'aide de Scilab, pour explorer rapidement les options de conception avec des modèles simplifiés (de dimension ‘0D’) avant d’entreprendre la conception détaillée avec des modèles plus raffinés (de dimensions ‘0D-1D’ à ‘3D-4D’), en vue de la certification puis de la mise en production de leurs produits. Dans l’approche de rupture poursuivie par ESI pour transformer le ‘Product Lifecycle Management’ (PLM) traditionnel, l’étape suivante du Prototypage Virtuel est de poursuivre la vie du produit au-delà des phases de développement et de certification, afin de couvrir sa vie réelle en fonctionnement opérationnel réel ou prévisionnel. Dans cette nouvelle approche méthodologique, intitulée «Product Performance Lifecycle» (PPL), le Prototype Virtuel ‘tel que fabriqué’ (‘as built’) est transformé en ‘Jumeau Virtuel Hybride’ (‘Hybrid Virtual Twin’) continument mis à jour par les données de capteurs ubiquistes pendant le fonctionnement réel ou hypothétique prévisionnel. Ici, les modèles mathématiques du produit - ainsi que ses capteurs réels ou virtuels et les systèmes de contrôle - sont essentiels pour fournir un prototypage prédictif fiable (‘data-driven’). Dans cette vision transformative du développement de bout en bout (‘end to end’) de produits innovants reliés à leur fonctionnement opérationnel, l'acquisition de Scilab Enterprises permet maintenant à ESI de répondre également aux premiers besoins techniques, à partir de modèles simples mais physiquement réalistes, avant d’évoluer vers les produits virtuels détaillés «tels que fabriqués» et «en fonctionnement» représentatifs des produits réels actuels construits par les clients, ou des produits assistés et autonomes de demain actuellement en développement. Après son acquisition réussie d’OpenCFD, société spécialisée en développements et services basés sur OpenFOAM®, également un logiciel open source pour la simulation numérique généralisée en mécanique des fluides, cette opération confirme l’engagement du Groupe pour le modèle économique open source et les changements transformationnels en faveur de la démocratisation des solutions d’ingénierie virtuelle. Cette approche permet de donner aux utilisateurs, avec des modalités flexibles et des coûts très abordables, une plus grande latitude en termes de personnalisation des applications et d’adaptabilité à leurs besoins. L´intégration de Scilab à l’écosystème mondial d’ESI devrait constituer, de ce fait, un levier majeur pour faciliter et accélérer la transformation numérique du développement de produits industriels innovants, connectés et intelligents. Scilab Enterprises et ESI Group bénéficieront naturellement des synergies tant en termes technologiques que commerciales. L'offre ESI Cloud actuelle sera grandement soutenue par cette acquisition et par la réputation de Scilab auprès d'une très grande communauté mondiale d'utilisateurs dans diverses industries et cercles académiques et de recherche. Elle représente également un atout majeur qui aidera à accroître la visibilité mondiale d'ESI et au final à créer de précieuses opportunités commerciales. En outre, la forte présence internationale de Scilab dans le domaine de l'éducation va immédiatement élargir la visibilité d'ESI dans ce secteur essentiel. En tant qu’éditeur du logiciel de modélisation et de simulation Scilab, Scilab Enterprises dispose d’une équipe resserrée d’experts composée de mathématiciens et d’ingénieurs informaticiens. Scilab est un logiciel open source largement utilisé parmi la communauté des scientifiques et ingénieurs (100 000 téléchargements chaque mois dans le monde). Le logiciel Scilab est utilisé pour la modélisation et la simulation et le post-traitement scientifique dans les entreprises industrielles mais également dans le secteur de l’éducation et de la recherche. Scilab Enterprises propose d’une part des services professionnels en calcul numérique et d’autre part met à disposition la plateforme ‘Scilab Cloud’ pour le déploiement d'applications scientifiques et techniques en mode Cloud. ESI Group est le principal créateur mondial de logiciels et services de Prototypage Virtuel. Spécialiste en physique des matériaux, ESI a développé un savoir-faire unique et innovant afin d’aider les industriels à remplacer les prototypes réels par des prototypes virtuels, leur permettant de fabriquer, assembler et tester leurs produits dans des environnements différents. Couplé à la Réalité Virtuelle, connecté à la modélisation des systèmes, et bénéficiant de l’analyse de données, le Prototypage Virtuel devient immersif, partagé et interactif : il permet aux clients d’ESI de mettre leurs produits à l’épreuve pour mieux garantir leur fiabilité et leur performance, et pour anticiper leur entretien et réparations. Les solutions d’ESI permettent aux grands donneurs d'ordres et aux entreprises innovantes d’anticiper et de s’assurer que leurs produits passeront les tests de certification – et ce, sans qu’aucun prototype réel ne soit nécessaire – les rendant plus compétitifs, dès leur arrivée sur le marché. Récemment, ESI a entrepris une adaptation transformante majeure de ses solutions de Prototypage Virtuel vers des « Jumeaux Hybrides Virtuels », pour entrer dans le nouveau paradigme du « Product Performance Lifecycle » (PPL). Le PPL aborde, au-delà de sa phase de développement, la nouvelle vie du produit dans son cycle complet de fonctionnement opérationnel, du lancement au retrait. Avec la nouvelle ère des capteurs omniprésents et connectés liés à l'Internet des objets (IoT), le PPL répond aux nouveaux besoins des industriels de créer sans relâche des produits innovants, intelligents, assistés et autonomes. ESI est présent dans les principaux secteurs industriels et emploie aujourd'hui plus de 1200 ingénieurs et scientifiques de haut-niveau à travers le monde, au service de ses clients répartis dans plus de 40 pays. ESI Group est une société française cotée sur le compartiment B d’Euronext Paris, labellisée « entreprise innovante » 2000 par Bpifrance (ex OSEO). ESI Group est éligible aux FCPI et aux PEA-PME.


News Article | February 28, 2017
Site: www.businesswire.com

SANTA ANA, Calif.--(BUSINESS WIRE)--Iteris, Inc. (NASDAQ: ITI), the global leader in applied informatics for transportation and agriculture, today announced that Scott Deeter, president and CEO of Ventria, has been elected to its Board of Directors. Deeter has served as Ventria's President and CEO and as a director since 2002. Ventria is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system. “We are very pleased for Scott to join Iteris as an independent director,” said Tom Thomas, Chairman of the Board for Iteris. “Our entire board is impressed with Scott’s proven business acumen and insights into emerging markets for technology, as well as his broad understanding of the agriculture value chain. As a highly regarded entrepreneur, Scott will contribute substantial value to Iteris, drawing on his extensive background in pioneering and commercializing new technologies.” “Iteris ClearAg® delivers science-based insights to make agriculture more sustainable and productive,” said Deeter. “There is a profound need to optimize the use of farmland to generate food, fiber and fuel for billions of people now and in the future. ClearAg, which is used by growers, crop scientists, and field service personnel around the world, is uniquely positioned to address this critical challenge.” Prior to Ventria, Deeter served as President and CEO and as a director of CyberCrop, a supply chain software company connecting producers with their markets to optimize quality, logistics and efficiency. Previously, Mr. Deeter started and led a joint venture between Cargill and F. Hoffmann-La Roche that commercialized pharmaceutical intermediates and functional food ingredients. Earlier in his career he was a member of the Technology and Life Sciences Group of Salomon Brothers. He is a graduate of the University of Kansas (BSc-Economics); University of Chicago (MBA); and London School of Economics (MSc-Economics). Iteris is the global leader in applied informatics for transportation and agriculture, turning big data into big breakthrough solutions. We collect, aggregate and analyze data on traffic, roads, weather, water, soil and crops to generate precise informatics that lead to safer transportation and smarter farming. Municipalities, government agencies, crop science companies, farmers and agronomists around the world use our solutions to make roads safer and travel more efficient, as well as farmlands more sustainable, healthy and productive. Visit www.iteris.com for more information. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This release may contain forward-looking statements, which speak only as of the date hereof and are based upon our current expectations and the information available to us at this time. Words such as "believes," "anticipates," "expects," "intends," “outlooks,” “target,” "plans," "seeks," "estimates," "may," "will," "can," and variations of these words or similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about the impact and expected contribution of our new director. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict, and actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Important factors that may cause such a difference include, but are not limited to, impact the new director will have on the company; our ability to be (and remain) competitive in new and existing market segments, and the impact of general economic, political and other conditions in the markets we address. Further information on Iteris, Inc., including additional risk factors that may affect our forward looking statements, is contained in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K, and our other SEC filings that are available through the SEC’s website (www.sec.gov).


News Article | February 16, 2017
Site: www.businesswire.com

SANTA ANA, Calif.--(BUSINESS WIRE)--Iteris, Inc. (NASDAQ: ITI), the global leader in applied informatics for transportation and agriculture, has been invited to present at the JMP Securities Technology Conference being held February 27-28, 2017 at The Ritz-Carlton, San Francisco at 600 Stockton Street. Iteris President and CEO Joe Bergera and CFO Andy Schmidt are scheduled to present on Monday, February 27, at 11:00 AM Pacific time, with one-on-one meetings held throughout the day. The presentation will be webcast live and available for replay via the investor relations section of the company’s website at www.iteris.com. For additional information or to schedule a one-on-one meeting with Iteris management, please contact your JMP representative, or Iteris’ investor relations firm, MKR Group, at ITI@mkr-group.com. Iteris is the global leader in applied informatics for transportation and agriculture, turning big data into big breakthrough solutions. We collect, aggregate and analyze data on traffic, roads, weather, water, soil and crops to generate precise informatics that lead to safer transportation and smarter farming. Municipalities, government agencies, crop science companies, farmers and agronomists around the world use our solutions to make roads safer and travel more efficient, as well as farmlands more sustainable, healthy and productive. Visit www.iteris.com for more information.


NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2016, and provided a corporate update. Intra-Cellular Therapies (the Company or ITCI) reported a net loss of $27.5 million, or $0.64 per share (basic and diluted), for the fourth quarter of 2016 compared to a net loss of $28.8 million, or $0.67 per share (basic and diluted), for the fourth quarter of 2015. The Company reported a net loss of $116.4 million, or $2.69 per share (basic and diluted), for the full year ended December 31, 2016 compared with a net loss of $104.8 million, or $2.91 per share (basic and diluted), for the full year ended December 31, 2015. Research and development (R&D) expenses for the fourth quarter of 2016 were $21.2 million, compared to $22.9 million for the fourth quarter of 2015. For the full year ended December 31, 2016, R&D expenses were $93.8 million, compared to $87.7 million for the full year ended December 31, 2015. The decrease for the quarter is primarily due to lower costs associated with the completion of the second Phase 3 clinical trial for lumateperone (also known as ITI-007) in patients with schizophrenia in the third quarter of 2016, offset in part by the costs of the Phase 3 clinical trials of lumateperone for the treatment of bipolar depression and agitation associated with dementia, including Alzheimer’s disease, and other clinical trials and increased manufacturing costs for lumateperone. The increase for the year is primarily due to an increase in manufacturing and labor related costs, offset in part by lower clinical trial related costs. There were decreased costs in 2016 for the first Phase 3 clinical trial for lumateperone in patients with schizophrenia that was completed in 2015. These lower costs were offset primarily by increased costs for the second Phase 3 clinical trial for lumateperone in patients with schizophrenia completed in the third quarter of 2016, along with the costs associated with the Phase 3 clinical trials of lumateperone for the treatment of bipolar depression and agitation associated with dementia, including Alzheimer’s disease, and other clinical trials. General and administrative (G&A) expenses were $7.0 million for the fourth quarter of 2016, compared to $6.5 million for the same period in 2015. For the full year ended December 31, 2016, G&A expenses were $24.8 million, compared to $18.2 million for the prior-year period. The increase in both periods is primarily the result of higher stock-based compensation expense and, to a lesser extent, professional fees, pre-commercialization activities and increased salaries. Cash and investments totaled $384.1 million at December 31, 2016, compared to $475.2 million at December 31, 2015. The Company expects that existing cash and investments of $384.1 million will be used primarily to advance the lumateperone development program, including to fund clinical trials of lumateperone in bipolar depression, behavioral disturbances in patients with dementia, depressive disorders and other lumateperone clinical trials and related clinical and non-clinical activities; to fund pre-commercial activities for lumateperone for the treatment of schizophrenia and, if lumateperone receives regulatory approval, initial commercialization efforts; to fund pre-clinical and clinical development of the Company’s ITI-007 long-acting injectable program; and to fund non-clinical activities including the continuation of manufacturing activities in connection with the development of lumateperone. Funds will also be used for other clinical and pre-clinical programs, including the Company’s phosphodiesterase (PDE) development activities. “Patients who suffer from neuropsychiatric and neurodegenerative disorders continue to be underserved by existing medications and we remain committed to developing innovative treatments that can provide broad efficacy without many of the safety and tolerability issues associated with current therapies,” said Dr. Sharon Mates, Chairman and CEO of ITCI. The Company will host a live conference call and webcast today at 8:30 AM Eastern Time to discuss the Company's financial results and provide a corporate update. The live webcast and subsequent replay may be accessed by visiting the Company's website at www.intracellulartherapies.com. Please connect to the Company's website at least 5-10 minutes prior to the live webcast to ensure adequate time for any necessary software download. Alternatively, please call 1-(844) 835-6563. (U.S.) or 1-(970) 315-3916 (international) to listen to the live conference call. The conference ID number for the live call is 72927263. Please dial in approximately 10 minutes prior to the call. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our expected use of our cash, cash equivalents and investment securities; our beliefs about the extent to which the results of our clinical trials to date support an NDA filing for lumateperone for the treatment of schizophrenia; the time period in which we expect to provide an update on the status of our discussions with the FDA; our clinical and non-clinical development plans; the initiation, progress, timing and results of our clinical trials; the safety and efficacy of our product development candidates; our beliefs about the potential uses and benefits of lumateperone; our plans to present additional data on our development programs; our beliefs about unmet medical needs and our research and development efforts and plans under the caption "About Intra-Cellular Therapies." All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to the following: our current and planned clinical trials and other studies for lumateperone and for our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development of our product candidates; and the other risk factors detailed in our public filings with the Securities and Exchange Commission. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law. (1) The condensed consolidated statements of operations for the years ended December 31, 2016 and 2015 have been derived from the financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. (1) The condensed consolidated balance sheets at December 31, 2016 and 2015 have been derived from the financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.


News Article | March 1, 2017
Site: www.businesswire.com

SANTA ANA, Calif.--(BUSINESS WIRE)--Iteris, Inc. (NASDAQ: ITI), the global leader in applied informatics for transportation and agriculture, has been invited to present at the 29th Annual ROTH Conference. The conference is being held on March 12-15, 2017 at The Ritz-Carlton in Dana Point, California. Iteris’ President and CEO Joe Bergera and CFO Andy Schmidt are scheduled to present on Tuesday, March 14 at 2:30 p.m. Pacific time, with one-on-one meetings held throughout the day. The presentation will be webcast live and available for replay at http://wsw.com/webcast/roth31/iti and via the investor relations section of the company’s website at www.iteris.com. For additional information or to schedule a one-on-one meeting with Iteris management, please contact your ROTH representative at 1-800-933-6830 or via e-mail at oneononerequests@roth.com. Iteris is the global leader in applied informatics for transportation and agriculture, turning big data into big breakthrough solutions. We collect, aggregate and analyze data on traffic, roads, weather, water, soil and crops to generate precise informatics that lead to safer transportation and smarter farming. Municipalities, government agencies, crop science companies, farmers and agronomists around the world use our solutions to make roads safer and travel more efficient, as well as farmlands more sustainable, healthy and productive. Visit www.iteris.com for more information.


News Article | December 7, 2016
Site: www.businesswire.com

ESI Group (Paris:ESI), leading innovator in Virtual Prototyping software and services for manufacturing industries, announces the signing of a long-term strategic partnership with PARC, a Xerox company and renowned provider of custom R&D and technology solutions to Global 1000 companies and government agencies. The partnership initially focuses on expanding and industrializing PARC’s advanced research project on Fault Augmented Model Extension (FAME), initiated with the Defense Advanced Research Projects Agency (DARPA). The partnership encompasses system reliability modeling, system safety assessment, predictive maintenance, and condition-based maintenance. These capabilities will come to strengthen the already existing ESI solutions dedicated to helping industrial manufacturers overcome engineering issues related to complex cyber-physical systems. As today’s industrial systems incorporate increasingly complex hardware and software sub-systems, an integrated model- and data-driven approach has become essential to address design, validation and operational issues throughout the system design and operations cycles. Over the years, ESI has been developing coherent and integrated virtual prototyping solutions that enable industrial customers to virtually manufacture and evaluate product performance in different environments and use cases. Today, ESI extends its proposition to smart virtual prototyping; giving its customers the ability to animate their virtual prototypes and use the latest technologies, including big data analytics and machine learning, to accurately predict and manage product operational performance from an early stage. ESI’s partnership with PARC marks the continuation of ESI’s strategic investments in system simulation. Indeed, in 2013, ESI acquired the cloud-based system design specialist CyDesign Labs, based in the Silicon Valley, and more recently the German company ITI GmbH, developer and vendor of SimulationX, the leading Modelica-based system simulation application in the field of System Modeling of cyber-physical systems. ESI has also complemented its data-driven system analytics capabilities by acquiring earlier this year Mineset Inc., specialized in web-based visual analytics and machine-learning and also based in the Silicon Valley. The research projects conducted in collaboration with PARC will accelerate the development of hybrid virtual prototyping and data-driven analytics solutions to maximize the useful and operationally reliable lifecycle of the products developed by ESI’s clients Tolga Kurtoglu, Vice President and Director of the System Sciences Lab (SSL) at PARC, remarks: “Industrial manufacturers want to minimize the cost of complex systems, while maximizing performance. Design teams need to be able to quantify reliability and mitigate risk at the earliest phase of the process. We will work with ESI in partnership to help customers identify problem areas, gain insight, and quantify the impact of component failure through time and use of a manufactured system’s lifecycle. Mature and complex industries, including transportation, aerospace, defense, and energy, will benefit from our FAME project, and we are thrilled to work with ESI Group to bring these capabilities to customers around the world.” Fadi Ben Achour, Electronics Business Development VP at ESI Group, comments on the long-term strategic partnership between ESI and PARC: “We are honored that such a highly regarded organization as PARC, with extensive expertise in system diagnostics, prognostics and condition based maintenance, has chosen ESI to industrialize one of their breakthrough technologies.” He continues: “Building on our existing expertise, the results from research conducted at PARC will enable ESI to deliver industrial solutions to answer system level challenges and to leverage the data generated by our customers systems during operations. Of course, we are also excited by the impact on our efforts to build a strong eco-system in San Francisco Bay Area and its hyper dynamic and innovative Silicon Valley." For additional information, please feel free to contact our international communications team: ESI Group is a leading innovator in Virtual Prototyping software and services. Specialist in material physics, ESI has developed a unique proficiency in helping industrial manufacturers replace physical prototypes by virtually replicating the fabrication, assembly and testing of products in different environments. Today, coupled with Virtual Reality, animated by systems models, and benefiting from data analytics, Virtual Prototyping becomes immersive and interactive: ESI’s clients can bring their products to life, ensuring reliable performance, serviceability and maintainability. ESI solutions help world-leading OEM’s and innovative companies make sure that their products will pass certification tests - before any physical prototype is built - and that new products are competitive in their market space. Virtual Prototyping addresses the emerging need for products to be smart and autonomous and supports industrial manufacturers in their digital transformation. Today, ESI’s customer base spans nearly every industry sector. The company employs about 1100 high-level specialists worldwide to address the needs of customers in more than 40 countries. For more information, please visit www.esi-group.com/


News Article | February 15, 2017
Site: phys.org

The surprise discovery about this important bonding relationship - between a metal ion and a coordinated group known as a ligand—from a team led by Professor Steve Liddle, has potential implications from cancer treatments to the nuclear power industry. Their ground-breaking research has now been published in the leading multi-disciplinary journal Nature Communications. Professor Liddle explained: "The arrangement of ligand groups at metal centres in metal-complexes is crucial to determining their reactivity. "For example, the molecule known as cis-platin is very effective at treating cancerous tumours whereas trans-platin is ineffective. Both compounds have the same molecular formula with a central platinum ion bonded to two chloride and two ammonia ligands, all in the same plane and in the shape of a cross—but in the former the chlorides are next to each other and in the latter they are on opposite sides to each other. "The arrangement of these ligands is therefore crucial to determining the reactivity of these complexes. The phenomenon that controls to a large extent the arrangement of ligands at metal centres is known as the trans-influence, which originates from the fact that some ligands bind to metals more strongly that others so ligands will avoid being opposite stronger donor ligands. This effect is observed right across the periodic table for most metals. "Conversely, down at the bottom of the periodic table, things can be quite different and for heavy elements like uranium a phenomenon known as the inverse-trans-influence (ITI) operates. "Here, ligands that would normally do everything they could to avoid being opposite each other at a metal, in fact, do everything they can to be oppositely disposed, and rather than this destabilising the ligands they actually mutually reinforce each other. "However, the ITI was previously limited only to actinides in their maximum or close or maximum oxidation states. A good example of this is the uranyl, {UO2}2+ ion which is widely prevalent in the environment naturally and also nuclear waste where the two oxygen atoms reside opposite each other and are bonded very strongly to the uranium. "This makes the uranyl moiety very important, but also the universal view that the ITI was a niche concept of limited applicability dominated because it was restricted to high oxidation state actinide metals like uranium. "So whether this phenomenon was a niche rule or hinted at a broader underpinning concept, in an area that has few rules and is essentially the 'Wild West' of the periodic table, had been a question that had endured for decades. "One reason this question had been difficult to tackle was the lack of structurally comparable families of molecules from which to conduct comparative studies where lower oxidation states of metal ions could be investigated." To address this problem, the research team prepared a new family of molecules with C=M=C cores where the metal was cerium [classed as a lanthanide] or thorium or uranium [which are classed as actinides] where two carbon atoms that are known to be strong donors were forced to be opposite to one another either side of the metal." Characterisation of this family of molecules required a team of researchers based at the Universities of Manchester, Lancaster, Nottingham, and Dresden, and the Rossendorf Beamline at Grenoble. Through this interdisciplinary effort the team was able to fully characterise the molecules and determine that the ITI operates in these molecules that contain metal ions in only the +4 oxidation state. The most notable observation is the fact that the two carbon atoms are bonded very closely to the metals, particularly for cerium, even though as strong donors they should be found at longer distances and this is a tell-tale sign of the ITI. Professor Liddle added: "The combination of finding the ITI in +4 metal ion complexes, as well as for lanthanide as well as actinide complexes leads to the conclusion that this phenomenon is most likely of far broader reach than previously thought. "Considering the prevalence of actinide elements in the environment naturally but also in nuclear waste, and that the structure of metal complexes is inherently linked to their reactivity, this research could help in waste clean-up in the future." More information: Matthew Gregson et al, The inverse-trans-influence in tetravalent lanthanide and actinide bis(carbene) complexes, Nature Communications (2017). DOI: 10.1038/ncomms14137

Loading ITI GmbH collaborators
Loading ITI GmbH collaborators